

**Oklahoma Health Care Authority  
Drug Utilization Review Board**

(DUR Board)

**Meeting – May 11, 2011 @ 6:00 p.m.**

Oklahoma Health Care Authority  
2401 N.W. 23<sup>rd</sup> Street, Suite 1-A  
Oklahoma City, Oklahoma 73107  
Ponca Room (North Entrance)

---

**AGENDA**

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
  - A. Roll Call – Dr. Graham

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
  - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
  - A. April 13, 2011 DUR Minutes – Vote
  - B. April 14, 2011 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
  - A. Retrospective Drug Utilization Review for March 2011
  - B. Retrospective Drug Utilization Review Response for December 2010
  - C. Medication Coverage Activity Audit for April 2011
  - D. Pharmacy Help Desk Activity Audit for April 2011

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

5. **Action Item – Vote to Prior Authorize Pradaxa<sup>®</sup> – See Appendix C.**
  - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman:

6. **Action Item – Vote to Prior Authorize Dulera<sup>®</sup> and Update Criteria – See Appendix D.**
  - A. Utilization Review of Long Acting Beta Agonists
  - B. COP Recommendations

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

7. **Action Item – Vote to Prior Authorize Sumavel<sup>®</sup> and Update Anti-Migraine PBPA Criteria – See Appendix E.**
  - A. Current Authorization Criteria
  - B. COP Recommendations

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

8. **Action Item – Annual Review of Anti-Ulcer Medications and Vote to Update Prior Authorization Criteria – See Appendix F.**
  - A. Current Authorization Criteria
  - B. Utilization Review
  - C. Prior Authorizations Review
  - D. Market News and Updates
  - E. Utilization Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

9. **Action Item – Vote to Update ADHD/Narcolepsy Prior Authorization Criteria – See Appendix G.**
  - A. Evaluation of New Products
  - B. COP Recommendations

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

10. **30 Day Notice to Prior Authorize Topical Corticosteroids – See Appendix H.**
  - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

11. **Questions Regarding Posted 30 Day Notices – See Appendix I.**
  - A. 30 Day Notice to Prior Authorize Adcirca<sup>®</sup>
  - B. 30 Day Notice to Prior Authorize Physician Administered Medications, including Benlysta<sup>®</sup>
  - C. 30 Day Notice to Prior Authorize Colcrys<sup>®</sup> and Uloric<sup>®</sup>
  - D. 30 Day Notice to Prior Authorize Miscellaneous Bladder Agents
  - E. 30 Day Notice to Prior Authorize Neudexta<sup>™</sup>
  - F. 30 Day Notice to Prior Authorize Testosterone Replacement Products

Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

12. **FDA and DEA Updates – See Appendix J.**

13. **Future Business**
  - A. Utilization Review of Diabetes Products
  - B. Annual Review of Anxiolytics
  - C. Annual Review of Antiemetics
  - D. Annual Review of Otic Antibiotics
  - E. New Product Reviews

14. **Adjournment**